<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0043346" disease_type="Neoplastic Process" abbrv="">Xeroderma pigmentosum</z:e> complementation group C and G (XPC, <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e>) play important roles in DNA damage repairing machinery </plain></SENT>
<SENT sid="1" pm="."><plain>Genetic variations in the XPC and <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e> may be associated with increased risk for colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we evaluated the relation between the XPC Lys939Gln, <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e> Asp1104His polymorphisms, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> susceptibility in a population-based case-control study, which included 1,028 CRC cases and 1,085 controls </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with the corresponding wild genotypes, we found that individuals with at least one copy of the XPC Lys939Gln (AC or CC genotype) and <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e> Asp1104His (GC or CC genotype) had an increased risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, the variant genotypes of the XPC Lys939Gln AC/CC (P = 0.027) or <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e> Asp1104His GC/CC (P = 0.003) reduced the elevation of preoperative carcinoembryonic antigen (CEA) level </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover a significantly longer progression-free survival (PFS) after <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi>-based adjuvant chemotherapy was observed in patients with <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e> Asp1104His wide-type GG genotype (n = 432, Log-rank test: P = 0.033) </plain></SENT>
<SENT sid="6" pm="."><plain>Cox proportional hazards analyses demonstrated that variant genotypes of <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e> Asp1104His [hazard ratio (HR)â€‰= 1.692, 95% confidence interval (95%CI): 1.202-2.383, P = 0.003] as well as pathology grade (HR = 2.545, 95%CI: 2.139-3.030, P &lt; 0.001), and <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> (HR = 1.851, 95%CI: 1.306-2.625, P &lt; 0.001) were predictive of shorter PFS for the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi>-based adjuvant chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, the current data suggested that XPC Lys939Gln and <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e> Asp1104His polymorphisms might contribute to the identification of patients with increased risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>